Valor202020212022202320242025TTMGastos comerciales, generales y administrativos96.06 M105.67 M116.99 M121 M117.5 M142.32 M142.32 MInvestigación y desarrollo17.85 M24.18 M27.16 M28.33 M27.77 M32.88 M32.88 MBeneficio operativo-23.18 M-25.42 M-29.71 M-21.46 M-3.29 M-7.85 M-7.85 MTotal de ingresos no operativos-604 K-1.57 M759 K-254 K-6.68 M-7.85 M-7.85 MGastos por intereses, netos de intereses capitalizados1.05 M1.36 M624 K2.83 M8.21 M7.7 M7.7 MIngresos no operativos, una vez deducidos los gastos por intereses-1.62 M-2.65 M365 K-2.65 M-14.68 M-15.72 M-15.72 MIngresos/gastos extraordinarios-38 K-278 K-230 K-437 K-199 K167 K167 KBeneficio antes de impuestos-24.02 M-26.99 M-29.84 M-22.61 M-18.17 M-23.41 M-23.41 MParticipación en los beneficios———————Impuestos0000000Participación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-23.79 M-26.98 M-28.95 M-21.72 M-9.96 M-15.7 M-15.7 MOperaciones suspendidas———————Beneficio neto-23.79 M-26.98 M-28.95 M-21.72 M-9.96 M-15.7 M-15.7 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-23.79 M-26.98 M-28.95 M-21.72 M-9.96 M-15.7 M-15.7 MBeneficio básico por acción—-0.65-0.69-0.51-0.23-0.34-0.34Beneficio por acción diluido—-0.65-0.69-0.51-0.23-0.34-0.34Número medio de acciones ordinarias—41.22 M42.08 M42.88 M44.26 M46.05 M183.81 MAcciones diluidas—41.22 M42.08 M42.88 M44.26 M46.05 M188.32 MEBITDA313 K4.01 M-2.73 M13.89 M48.54 M56.67 M56.67 MEBIT-1.6 M-2.48 M-5.56 M9.68 M42.07 M50.01 M50.01 MCosto de los ingresos21.58 M22.93 M24.15 M31.14 M45.36 M57.85 M57.85 MOtros costes de producción2.24 M3.31 M1.77 M1.94 M6.99 M4.53 M—Amortización y depreciación (flujo de caja)1.91 M6.5 M2.83 M4.22 M6.47 M6.66 M6.66 M
Axogen Inc
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use.